Live
Audio Only
This vaccine showed 95.47 percent of effectiveness in Phase 3 of clinical trials.
Mexico's Foreign Affairs Minister Marcelo Ebrard on Thursday announced the beginning of the first massive production of the COVID-19 vaccine developed by the Chinese CanSino Biologics company.
RELATED:
The vaccine will be produced in Drugmex headquarters, a subsidiary of the Argentine company Dromex, in Queretaro.
The production will monitor the vaccine's stability and purity to ensure a safe application. So far, Mexico has pre-purchased 35 million CanSino doses.
Phase III clinical trials' results showed that the vaccine was 95.47 percent effective after 14 days of its application.
Good health news!
— United Nations (@UN) February 24, 2021
Ghana has become the first country to receive #COVID19 vaccines through COVAX, a UN-led initiative to ensure equitable vaccine access for everyone.
More on this historic step to end the pandemic. https://t.co/v5aGuCCM50 pic.twitter.com/aQPFTKjd93
On Feb. 11, the first CanSino batch made up of 2 million doses arrived in the country where people will be immunized with a single shot.
Having vaccinated health personnel in the first stage, Mexico began phase 2 of its immunization plan which covers over 15 million adults over 60 years of age.
As of Friday morning, the country had confirmed 2,069,370 COVID-19 cases and 183,692 related deaths.
Since the Covid-19 pandemic, more than 16 million people across Latin America have sunk into poverty. pic.twitter.com/L7wTrB8Hkp
— teleSUR English (@telesurenglish) February 9, 2021
Newsletter
